Nitroimidazole substituted porphyrin complex
AssigneePhotochemical Co., Ltd.
InventorsIsao Sakata, Susumu Nakajima, Yoshinori Nakae
Life of this patent
Estimating the term…
Abstract
The present invention provides the porphyrin compound having nitroimidazole in the molecule, which is used for diagnosis and/or treatment of cancer in magnetic resonance imaging (MRI) and/or radiotherapy as well as for DDS therapy. The porphyrin compound of the present invention shows no phototoxicity, and represented by the following formula: [wherein, R1 and R2 are —CH═CH2 or —CH(CH3)—OH, —CH(CH3)—O—(CH2)n—NH—Ra; R3 is hydrogen atom or —CO—(CH2)m—COOH; and M is transition metal of Mn, Fe, Co or Cu], (in which, Ra is hydrogen atom or the group represented by the following formula: n and m are the integer 2 or 3), or a pharmaceutically acceptable salt thereof.
Claims20
A porphyrin metal complex represented by the following formula (I):
- [wherein,
- when one of R1 and R2 is —CH═CH2 or —CH(CH3)—OH, the other is —CH(CH3)—O—(CH2)n—NH—Ra;
- or both of R1 and R2 are —CH(CH3)—O—(CH2)n—NH—Ra;
- R3 is hydrogen atom or —CO—(CH2)m—COOH;
- M is transition metal of Mn, Fe, Co or Cu],
- in which, Ra is hydrogen atom or the group represented by the following formula:
- n and m are the integer 2 or 3,
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.